The mammalian target of rapamycin complex 1 (mTORC1) integrates mitogen and nutrient signals to control cell proliferation and cell size. Hence, mTORC1 is implicated in a large number of human diseases--including diabetes, obesity, heart disease, and cancer--that are characterized by aberrant cell growth and proliferation. Although eukaryotic translation initiation factor 4E-binding proteins (4E-BPs) are critical mediators of mTORC1 function, their precise contribution to mTORC1 signaling and the mechanisms by which they mediate mTORC1 function have remained unclear. We inhibited the mTORC1 pathway in cells lacking 4E-BPs and analyzed the effects on cell size, cell proliferation, and cell cycle progression. Although the 4E-BPs had no effect on cell size, they inhibited cell proliferation by selectively inhibiting the translation of messenger RNAs that encode proliferation-promoting proteins and proteins involved in cell cycle progression. Thus, control of cell size and cell cycle progression appear to be independent in mammalian cells, whereas in lower eukaryotes, 4E-BPs influence both cell growth and proliferation.The mammalian target of rapamycin complex 1 (mTORC1) controls growth (increase in cell mass) and proliferation (increase in cell number) by modulating mRNA translation through phosphorylation of the eukaryotic translation initiation factor 4E (eIF4E)-binding proteins (4E-BP1, 2, and 3) and the ribosomal protein S6 kinases (S6K1 and 2) (1,2). 4E-BPs regulate the translation of a subset of mRNAs by competing with eIF4G for binding to eIF4E, thus preventing the assembly of the eIF4F complex, whereas the S6Ks control the phosphorylation status of a number of translational components (1-3). Rapamycin has been an important tool in understanding mTORC1 signaling; however, it inefficiently and transiently inhibits 4E-BP phosphorylation (4)( fig. S1A). Moreover, we found that rapamycin inhibited proliferation and G1/S cell cycle progression of WT and 4E-BP double knock-out (DKO) mouse embryonic fibroblasts (MEFs) to the same extent, which suggests that its effects are not mediated by 4E-BPs ( fig. S1, B to D). To directly address the role of 4E-BPs in mTORC1 signaling, we depleted raptor, a component of mTORC1 required for substrate binding (5), in these MEFs. 4E-BP DKO MEFs lack all three 4E-BPs as they do not express 4E-BP3 ( fig. S2A) 1A). Wild-type MEFs in which raptor was depleted proliferated more slowly than control cells, whereas raptor-depleted 4E-BP DKO MEFs proliferated at a rate indistinguishable from that of control cells (Fig. 1B). Similarly, in human embryonic kidney (HEK) 293T cells, raptor silencing had a pronounced effect on mTORC1 signaling and proliferation (Figs. 1C and D). The effect of raptor silencing on proliferation, but not mTOR signaling, was attenuated by codepletion of 4E-BPs (Fig. 1D). Thus, mTORC1-dependent proliferation requires 4E-BPs.To further assess the role of 4E-BPs in mTORC1-mediated cell proliferation, we depleted mTOR or rictor (an mTORC2 specific component), i...

Studies on various forms of synaptic plasticity have demonstrated a link between mRNA translation, learning and memory. Like memory, synaptic plasticity includes an early phase which depends on modification of pre-existing proteins, and a late phase that requires transcription and synthesis of new proteins 1,2 . Activation of post-synaptic targets appears to trigger the transcription of plasticityrelated genes. The new mRNAs are either translated in the soma or transported to synapses before translation. GCN2, a key protein kinase, regulates the initiation of translation. We now report a unique feature of hippocampal slices from GCN2 -/-mice: in CA1, a single 100 Hz train induces a strong and sustained long-term potentiation (late-LTP or L-LTP), which is transcription and translation dependent. In contrast, stimulation that elicits late-LTP in wild type slices, such as four 100 Hz trains or forskolin, fails to evoke L-LTP in GCN2 -/-slices. This aberrant synaptic plasticity is mirrored in the behavior of GCN2 -/-mice in the Morris water maze: after weak training, their spatial memory is enhanced, but it is impaired after more intense training. Activated GCN2 stimulates mRNA translation of ATF4, a CREB antagonist. Accordingly, in the hippocampus of GCN2 -/-mice, the expression of ATF4 is reduced and CREB activity is increased. Our study provides genetic, physiological, behavioral and molecular evidence that GCN2 regulates synaptic plasticity, as well as learning and memory through modulation of the ATF4/CREB pathway.Translation of eukaryotic mRNAs is primarily regulated at the level of initiation 3 . Binding of the initiator tRNA, Met-tRNA i Met , to the 40S subunit is facilitated by the initiation factor 2 (eIF2) which forms a ternary complex with GTP and Met-tRNA i Met . Although phosphorylation

SH3 and multiple ankyrin repeat domains 3 (SHANK3) haploinsufficiency is causative for the neurological features of Phelan-McDermid syndrome (PMDS), including a high risk of autism spectrum disorder (ASD). We used unbiased, quantitative proteomics to identify changes in the phosphoproteome of Shank3-deficient neurons. Down-regulation of protein kinase B (PKB/Akt)-mammalian target of rapamycin complex 1 (mTORC1) signaling resulted from enhanced phosphorylation and activation of serine/threonine protein phosphatase 2A (PP2A) regulatory subunit, B56β, due to increased steady-state levels of its kinase, Cdc2-like kinase 2 (CLK2). Pharmacological and genetic activation of Akt or inhibition of CLK2 relieved synaptic deficits in Shank3-deficient and PMDS patient-derived neurons. CLK2 inhibition also restored normal sociability in a Shank3-deficient mouse model. Our study thereby provides a novel mechanistic and potentially therapeutic understanding of deregulated signaling downstream of Shank3 deficiency.

Background: mTORC1 is dysregulated in human disease, and there is an interest in the development of mTORC1 inhibitors. Niclosamide inhibits mTORC1 signaling, but its mode of action remains unclear. Results: Niclosamide extrudes protons from lysosomes, thus lowering cytoplasmic pH and inhibiting mTORC1 signaling. Conclusion: Cytoplasmic acidification inhibits mTORC1 signaling. Significance: Our findings may aid the design of niclosamide-based anticancer therapeutic agents.

Regulation of translation factor activity plays a major role in protein synthesis-dependent forms of synaptic plasticity. We examined translational control across the critical period of Arc synthesis underlying consolidation of long term potentiation (LTP) in the dentate gyrus of intact, anesthetized rats. LTP induction by high frequency stimulation (HFS) evoked phosphorylation of the cap-binding protein eukaryotic initiation factor 4E (eIF4E) and dephosphorylation of eIF2␣ on a protracted time course matching the time-window of Arc translation. Local infusion of the ERK inhibitor U0126 inhibited LTP maintenance and Arc protein expression, blocked changes in eIF4E and eIF2␣ phosphorylation state, and prevented initiation complex (eIF4F) formation. Surprisingly, inhibition of the mTOR protein complex 1 (mTORC1) with rapamycin did not impair LTP maintenance or Arc synthesis nor did it inhibit eIF4F formation or phosphorylation of eIF4E. Rapamycin nonetheless blocked mTOR signaling to p70 S6 kinase and ribosomal protein S6 and inhibited synthesis of components of the translational machinery. Using immunohistochemistry and in situ hybridization, we show that Arc protein expression depends on dual, ERK-dependent transcription and translation. Arc translation is selectively blocked by pharmacological inhibition of mitogen-activated protein kinase-interacting kinase (MNK), the kinase coupling ERK to eIF4E phosphorylation. Furthermore, MNK signaling was required for eIF4F formation. These results support a dominant role for ERK-MNK signaling in control of translational initiation and Arc synthesis during LTP consolidation in the dentate gyrus. In contrast, mTORC1 signaling is activated but nonessential for Arc synthesis and LTP. The work, thus, identifies translational control mechanisms uniquely tuned to Arc-dependent LTP consolidation in live rats.The adult mammalian brain is known to express diverse forms of activity-dependent synaptic plasticity (1, 2). Bursts of synaptic activity can induce short term changes in synaptic strength, but more stable modifications typically require modulation of gene expression at the transcriptional and post-transcriptional levels (3, 4). Through post-transcriptional regulation, synaptic activity may dictate the time and place of neuronal protein synthesis.Regulated phosphorylation of translation factors and other ribosome-associated proteins is a major mechanism for controlling the activity of the translational machinery (5, 6). Translation control studies of LTP 2 have concentrated mainly on the Schaffer-collateral input to hippocampal CA1 pyramidal cells. Studies employing knock-out mice and pharmacological inhibitors support a role for eukaryotic initiation factor 4E (eIF4E) and eIF2␣ in consolidation of LTP in the CA1 region and long term memory (7-10). The function of the cap-binding protein eIF4E during translational initiation is controlled by eIF4E-binding proteins (4E-BPs), which inhibit initiation complex (eIF4F) formation by competing with the scaffolding protein eIF4G for...

eIF4E, the mRNA 5' cap-binding translation initiation factor, is overexpressed in numerous cancers and is implicated in mechanisms underlying oncogenesis and senescence. 4E-BPs (eIF4E-binding proteins) inhibit eIF4E activity, and thereby act as suppressors of eIF4E-dependent pathways. Here, we show that tumorigenesis is increased in p53 knockout mice that lack 4E-BP1 and 4E-BP2. However, primary fibroblasts lacking 4E-BPs, but expressing p53, undergo premature senescence and resist oncogene-driven transformation. Thus, the p53 status governs 4E-BP-dependent senescence and transformation. Intriguingly, the 4E-BPs engage in senescence via translational control of the p53-stabilizing protein, Gas2. Our data demonstrate a role for 4E-BPs in senescence and tumorigenesis and highlight a p53-mediated mechanism of senescence through a 4E-BP-dependent pathway.

Summary The eIF4E-binding proteins (4E-BPs) repress translation initiation by preventing eIF4F complex formation. Of the three mammalian 4E-BPs, only 4E-BP2 is enriched in the mammalian brain and plays an important role in synaptic plasticity and learning and memory formation. Here we describe asparagine deamidation as brain-specific posttranslational modification of 4E-BP2. Deamidation is the spontaneous conversion of asparagines to aspartates. Two deamidation sites were mapped to an asparagine-rich sequence unique to 4E-BP2. Deamidated 4E-BP2 exhibits increased binding to the mammalian Target of Rapamycin (mTOR)-binding protein raptor, which effects its reduced association with eIF4E. 4E-BP2 deamidation occurs during postnatal development, concomitant with the attenuation of the activity of the PI3K-Akt-mTOR signalling pathway. Expression of deamidated 4E-BP2 in 4E-BP2−/− neurons yielded mEPSCs exhibiting increased charge transfer with slower rise and decay kinetics, relative to the wild type form. 4E-BP2 deamidation may represent a compensatory mechanism for the developmental reduction of PI3K-Akt-mTOR signalling.

The G2019S mutation in the multidomain protein leucine-rich repeat kinase 2 (LRRK2) is one of the most frequently identified genetic causes of Parkinson’s disease (PD). Clinically, LRRK2(G2019S) carriers with PD and idiopathic PD patients have a very similar disease with brainstem and cortical Lewy pathology (α-synucleinopathy) as histopathological hallmarks. Some patients have Tau pathology. Enhanced kinase function of the LRRK2(G2019S) mutant protein is a prime suspect mechanism for carriers to develop PD but observations in LRRK2 knock-out, G2019S knock-in and kinase-dead mutant mice suggest that LRRK2 steady-state abundance of the protein also plays a determining role. One critical question concerning the molecular pathogenesis in LRRK2(G2019S) PD patients is whether α-synuclein (aSN) has a contributory role. To this end we generated mice with high expression of either wildtype or G2019S mutant LRRK2 in brainstem and cortical neurons. High levels of these LRRK2 variants left endogenous aSN and Tau levels unaltered and did not exacerbate or otherwise modify α-synucleinopathy in mice that co-expressed high levels of LRRK2 and aSN in brain neurons. On the contrary, in some lines high LRRK2 levels improved motor skills in the presence and absence of aSN-transgene-induced disease. Therefore, in many neurons high LRRK2 levels are well tolerated and not sufficient to drive or exacerbate neuronal α-synucleinopathy.